Page values for "Aducanumab"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | |
| brand | String | Aduhelm |
| structure | File | |
| classes | List of String, delimiter: , | Anti-amyloid beta (Aβ) monoclonal antibody |
| mechanism | String | Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. |
| uses | String | Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. |
| starting_dose | String | Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w |
| preparations | String | Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion |
| fda_max | String | Withdrawn 2024 |
| pill_id | Text | |
| routes | List of String, delimiter: , | IV infusion every 4 weeks |
| onset | String | PET Aβ reduction over months |
| duration | String | Withdrawn |
| halflife | String | ~25 days |
| bioavailability | String | 100% (IV) |
| pregnancy | String | Discontinued/withdrawn |
| legal | String | Withdrawn from US market January 2024 |